Gritstone bio details progress in cancer vaccine trials By Investing.com
Gritstone bio (GRTS) has unveiled promising preliminary data from its GRANITE personalized cancer vaccine program during its First Quarter 2024 Earnings Call. The clinical updates showed a positive trend in progression-free survival (PFS)…
